Fed. Circ.'s Vimovo Ruling Harms Innovation, Horizon Says

By Dani Kass (June 17, 2019, 9:22 PM EDT) -- The Federal Circuit has heightened the standard for patenting new drugs by requiring companies to prove that new inventions are effective to satisfy written description requirements, Horizon Pharma and Nuvo Pharmaceuticals said in a bid to get two patents for the pain reliever Vimovo revived....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!